MHRA join the speaker line-up at 6th annual RNA Therapeutics Summit

By: SMi Group
 
 
RNA Therapeutics 2015
RNA Therapeutics 2015
LONDON - Feb. 3, 2015 - PRLog -- SMi Group are delighted to announce that John Johnston, MHRA Clinical Assessor from the Biologicals & Biotechnology Unit, will be joining the expert panel at it’s 6th annual RNA Therapeutics conference, taking place on 16th & 17th February in Central London. The presentation entitled: Quick Tips, will discuss The MHRA Innovation Office and the hypothesis and objectives of a clinical study with a focus on clinical endpoints and surrogate markers.

Other event highlights:

1. AstraZeneca share clinical data on modulating intractable oncology targets: Next generation ASO technology is poised to become a key therapeutic modality to modulate intractable oncology targets. Chief Scientist, David Blakey will be presenting clinical data in his keynote address entitled: Tackling Intractable targets in oncology.

2. Roche unlock the potential with locked nucleic acids: Roche recently announced the launch of the SeqCap RNA Target Enrichment System for RNA-Seq applications. The system was designed to enable researchers to achieve significantly enhanced discovery power and targeting efficiency of RNA-Seq. Hear more as Vice President of Drug Discovery & Alliance, Bo Rode Hansen, explains the most recent thinking on increasing productivity of RNA therapeutics development.

3. GSK answer the question: How do we deliver macromolecules to the right address?GSK Director, Steven Hood will answer this and more in a presentation that discusses pharmacological evaluation in vitro and in vivo, bioconjugates, nanoassemblies and cell/tissue imaging.

4. Industry KOL Dirk Haussecker provides an opening keynote on Day 2: "My perspective is somewhat unique as I can draw on both my scientific and financial experiences in this area and maintain an active dialogue with the drug developers, basic scientists, and investors in this field. Conference delegates should come away with a better understanding on the macrostructural dynamics in the industry."

5. Sarepta Therapeutics present findings from a 120 week trial: Distinguished Scientist, Ryszard Kole will be presenting the results from a continuing trial after 120 weeks of treatment. The keynote address entitled: From RNA splicing to Eterplirsen trials - a drug for Duchenne muscular dystrophy, will provide insight into Eteplirsen induced exon skipping of 51 in dystrophin pre-mRNA in DMD patients and showcase the invention of RNA splicing modulation

This is just a snapshot of what will be covered. Other key speakers will include Silence Therapeutics, CRISPR Therapeutics, Leiden University Medical Centre, UCL and University of Oxford.

For further details visit the website at: http://www.smi-online.co.uk/pharmaceuticals/uk/conference...

RNA Therapeutics 2015

16 - 17 Feb 2015
Marriott Regents Park Hotel, London, UK
http://www.smi-online.co.uk/pharmaceuticals/uk/conference/rnai-nano-technology
Sponsored by Lipocalyx and Silence Therapeutics

--- END ---

About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the worlds most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Contact
SMi Group
***@smi-online.co.uk
End
Source:SMi Group
Email:***@smi-online.co.uk Email Verified
Tags:Rna, Formulations, Rnai, GENE SPLICING, Mhra
Industry:Biotech, Science
Location:London City - London, Greater - England
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
SMi Group Ltd. News
Trending
Most Viewed
Daily News



Like PRLog?
9K2K1K
Click to Share